60 Participants Needed

Nifedipine ER for Postpartum High Blood Pressure

(IPAT Trial)

AP
JK
ZP
Overseen ByZaira Peterson
Age: 18 - 65
Sex: Female
Trial Phase: Phase 3
Sponsor: Medical College of Wisconsin
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial
Approved in 3 JurisdictionsThis treatment is already approved in other countries

Trial Summary

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

What data supports the effectiveness of the drug Nifedipine ER for postpartum high blood pressure?

Research shows that Nifedipine, a drug that lowers blood pressure, can significantly reduce mean arterial pressure (average blood pressure in the arteries) and increase urine output in postpartum patients with severe preeclampsia, indicating its effectiveness in managing high blood pressure after childbirth.12345

Is Nifedipine ER safe for treating high blood pressure in postpartum women?

Nifedipine, used for treating high blood pressure, has been studied for safety in various conditions, including pregnancy-related hypertension. Common side effects include flushing (redness and warmth in the face) and headaches, which often decrease over time. Ankle swelling may occur and might not improve with continued use.12678

How is the drug Nifedipine ER unique for treating postpartum high blood pressure?

Nifedipine ER is unique because it is a calcium channel blocker that not only lowers blood pressure but also increases urine output, which can be beneficial in managing postpartum high blood pressure, especially in cases of severe preeclampsia. It also has the advantage of being taken orally, which can be more convenient compared to other treatments.124910

What is the purpose of this trial?

The long-term goal of our work is to evaluate the effect of intensive postpartum blood pressure control on maternal cardiovascular health, risk of chronic hypertension, and reversal of vascular dysfunction generated by hypertensive disorders of pregnancy, thus attenuating the lifelong trajectory of cardiovascular disease risk.

Eligibility Criteria

This trial is for women aged 18-45 who have been diagnosed with high blood pressure or pre-eclampsia during pregnancy, according to ACOG guidelines. They must be within the first three days postpartum and able to communicate in English or Spanish. Women with pre-existing hypertension, diabetes before pregnancy, plans to transfer hospitals postpartum, nifedipine allergies, or unwillingness to consent are excluded.

Inclusion Criteria

I have been diagnosed with high blood pressure during pregnancy.
I can communicate in English or Spanish.
Postpartum day 0-3 and prior to discharge

Exclusion Criteria

Known allergy to nifedipine or other significant contraindication to nifedipine
Inability or unwillingness to provide informed consent
Intent to transfer postpartum to an outside institution of the participating centers
See 2 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Intensive postpartum BP control with Nifedipine ER versus usual care for 6 weeks postpartum

6 weeks
Monthly virtual educational sessions

Follow-up

Participants are monitored for cardiovascular health, BP, and vascular function up to 12 months postpartum

12 months
Assessments at baseline, 6 weeks, and 12 months postpartum

Treatment Details

Interventions

  • NIFEdipine ER
Trial Overview The study is testing the effects of intensive blood pressure control using NIFEdipine ER after childbirth on long-term cardiovascular health. It aims to reduce chronic hypertension risk and improve vascular function affected by hypertensive disorders during pregnancy.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: Intervention armExperimental Treatment1 Intervention
Intervention group - intensive postpartum BP control with Nifedipine initiation at SBP≥140 mmHg or DBP≥90 mmHg and maintaining BP at \<140/90 mmHg during the first 6 weeks postpartum. In addition, participants will receive education on healthy lifestyle following AHA LE8.
Group II: Active control armActive Control1 Intervention
Active control group - a group of usual care that follows ACOG recommendations with Nifedipine initiation at SBP≥150 mmHg or DBP≥100 mm Hg and maintaining BP at \<150/100 mmHg during the first 6 weeks postpartum. In addition, participants will receive education on healthy lifestyle following AHA LE8.

NIFEdipine ER is already approved in European Union, United States, Canada for the following indications:

🇪🇺
Approved in European Union as Nifedipine for:
  • Hypertension
  • Angina pectoris
  • Vasospastic angina
🇺🇸
Approved in United States as Nifedipine for:
  • Hypertension
  • Angina pectoris
  • Vasospastic angina
  • Chronic stable angina
🇨🇦
Approved in Canada as Nifedipine for:
  • Hypertension
  • Angina pectoris
  • Vasospastic angina

Find a Clinic Near You

Who Is Running the Clinical Trial?

Medical College of Wisconsin

Lead Sponsor

Trials
645
Recruited
1,180,000+

Findings from Research

Nifedipine is considered a safe and effective second-line treatment for hypertension in pregnancy, helping to lower blood pressure and reduce risks of serious maternal complications like cerebral hemorrhage.
While nifedipine shows maternal benefits, its effects on perinatal outcomes are not yet fully established, indicating the need for further clinical trials before it can be recommended as a first-line treatment.
Use of nifedipine in the hypertensive diseases of pregnancy.Levin, AC., Doering, PL., Hatton, RC.[2017]
In a randomized trial involving 110 participants with preeclampsia, the use of extended-release nifedipine significantly reduced the need for acute hypertension treatment during labor, with a relative risk of 0.62 compared to placebo.
The nifedipine group also had a lower rate of cesarean deliveries (20.8% vs. 34.7%) and fewer admissions to the neonatal intensive care unit (29.1% vs. 47.1%), suggesting potential benefits for both maternal and neonatal outcomes.
Trial of Intrapartum Extended-Release Nifedipine to Prevent Severe Hypertension Among Pregnant Individuals With Preeclampsia With Severe Features.Cleary, EM., Racchi, NW., Patton, KG., et al.[2023]
Nifedipine is more effective than other antihypertensives in controlling blood pressure in pregnant women with severe preeclampsia, based on a meta-analysis of nine trials involving 764 women.
Nifedipine also helps prolong gestation without increasing the risk of neonatal respiratory distress syndrome or perinatal deaths, indicating it is a safe option for managing severe preeclampsia.
[Clinical efficacy and perinatal outcome of nifedipine for severe preeclampsia: meta-analysis].Liu, QQ., Yu, YH., Gong, SP., et al.[2013]

References

Use of nifedipine in the hypertensive diseases of pregnancy. [2017]
Trial of Intrapartum Extended-Release Nifedipine to Prevent Severe Hypertension Among Pregnant Individuals With Preeclampsia With Severe Features. [2023]
[Clinical efficacy and perinatal outcome of nifedipine for severe preeclampsia: meta-analysis]. [2013]
The use of nifedipine during the postpartum period in patients with severe preeclampsia. [2022]
Sublingual nifedipine in human pregnancy. [2019]
Safety and efficacy of nifedipine 20 mg tablets in hypertension using electronic data collection in general practice. [2022]
[Adverse effects and hemodynamic effects of nifedipine as a tocolytic]. [2015]
The effect of nifedipine on oral contraceptive-induced hypertension in rats. [2013]
Nifedipine in acute hypertensive emergencies in pregnancy. [2014]
Nifedipine as a second line antihypertensive drug in pregnancy. [2019]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security